hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
=== Abuse of Coalition POWs === During the conflict, coalition aircrew shot down over Iraq were displayed as prisoners of war on TV, most with visible signs of abuse. Amongst several testimonies to poor treatment, USAF Captain Richard Storr was allegedly tortured by Iraqis during the Persian Gulf War. Iraqi secret police broke his nose, dislocated his shoulder and punctured his eardrum. Royal Air Force Tornado crew John Nichol and John Peters have both alleged that they were tortured during this time. Nichol and Peters were forced to make statements against the war on television. Members of British Special Air Service Bravo Two Zero were captured while providing information about an Iraqi supply line of Scud missiles to coalition forces. Only one, Chris Ryan, evaded capture while the group's other surviving members were violently tortured. Flight surgeon (later General) Rhonda Cornum was sexually assaulted by one of her captors after the Black Hawk helicopter in which she was riding was shot down while searching for a downed F-16 pilot.
Big dynorphin is an endogenous opioid peptide of the dynorphin family. It forms when a precursor protein prodynorphin is not fully processed, resulting in a 32-amino acid molecule containing both dynorphin A and dynorphin B sequences. It has the amino acid sequence: Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln-Lys-Arg-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr. Big dynorphin is a highly efficiacious principal endogenous agonist at the human κ-opioid receptor (KOR). It produces one of the strongest responses at GPR139 receptor among dynorphins. Additionally, it uniquely modulates NMDA receptor and potentiates acid-sensing ion channel 1a (ASIC1a). It plays a role in pain and stress responses. It exhibits both analgesic and pro-nociceptive properties. In mice it modulates memory and learning, and has anxiolytic properties, contributing to homeostatic regulation of opioid signaling in the central nervous system.
==== Caesarean section ==== Women are less likely to start breastfeeding after caesarean delivery compared with vaginal delivery. Though the stress of a caesarean section (c-section) may impact let-down and flow, and though time for recovery immediately after surgery may be needed, women who give birth via c-section are still able to breastfeed. Generally, the benefits of breastfeeding outweigh the harms posed by pain medications following surgery. Mothers may need to experiment with different breastfeeding positions to avoid putting pressure on the incision.
Sources: en.wikipedia.org
Trisenox – Almac Pharma – 1 mg/mL concentrate for intravenous therapy. Trisenox is packaged in 10 mL ampoules for single use. The ampoules contain a pure solution of arsenic trioxide, without preservatives, and also contain sodium hydroxide and hydrochloric acid. The solution has a pH of 7–9. The drug should be stored at room temperature and must not be frozen. After withdrawing the solution from the ampoule, it should be diluted in 100–250 mL of 5% glucose or saline solution. Arsenic trioxide should not be mixed or administered in the same infusion with other medications. In pharmaceutical compounding, arsenic trioxide was used in a 1:10 trituration with lactose (Trituratio Acidi arsenicosi 1/10). To prepare the trituration, one part arsenic trioxide is placed in a mortar, and while continuously grinding, nine parts of lactose are added in portions. Achieving a uniformLy distributed trituration requireson
Until the early 20th century, scientists assumed that the majority of synaptic communication in the brain was electrical. However, through histological examinations by Ramón y Cajal, a 20 to 40 nm gap between neurons, known today as the synaptic cleft, was discovered. The presence of such a gap suggested communication via chemical messengers traversing the synaptic cleft, and in 1921 German pharmacologist Otto Loewi confirmed that neurons can communicate by releasing chemicals. Through a series of experiments involving the vagus nerves of frogs, Loewi was able to manually slow the heart rate of frogs by controlling the amount of saline solution present around the vagus nerve. Upon completion of this experiment, Loewi asserted that sympathetic regulation of cardiac function can be mediated through changes in chemical concentrations. Furthermore, Otto Loewi is credited with discovering acetylcholine (ACh) – the first known neurotransmitter.
In 1982 the film critic Gianni Rondolino created Festival Internazionale Cinema Giovani, which later became the Torino Film Festival. Today Turin is one of the main cinematographic and television centres in Italy, thanks to the role of the Turin Film Commission that reports the production of many feature films, soap operas and commercials. Turin streets were the locations where Audrey Hepburn played War and Peace, Michael Caine drove a Mini Cooper in The Italian Job, Claudio Bisio becomes the president of the Italian Republic, Carlo Verdone set his version of Cinderella, Marco Tullio Giordana shot Piazza Fontana: The Italian Conspiracy, Woody Allen shot Hannah and Her Sisters, Cate Blanchett played Heaven, Giovanna Mezzogiorno Vincere, Marcello Mastroianni and Jacqueline Bisset The Sunday Woman, and Harvey Keitel The Stone Merchant. Turin also became the capital of the tsar for The Demons of St. Petersberg.
In humans, the total female diploid nuclear genome per cell extends for 6.37 Gigabase pairs (Gbp), is 208.23 cm long and weighs 6.51 picograms (pg). Male values are 6.27 Gbp, 205.00 cm, 6.41 pg. Each DNA polymer can contain hundreds of millions of nucleotides, such as in chromosome 1. Chromosome 1 is the largest human chromosome with approximately 220 million base pairs, and would be 85 mm long if straightened. In eukaryotes, in addition to nuclear DNA, there is also mitochondrial DNA (mtDNA) which encodes certain proteins used by the mitochondria. The mtDNA is usually relatively small in comparison to the nuclear DNA. For example, the human mitochondrial DNA forms closed circular molecules, each of which contains 16,569 DNA base pairs, with each such molecule normally containing a full set of the mitochondrial genes. Each human mitochondrion contains, on average, approximately 5 such mtDNA molecules. Each human cell contains approximately 100 mitochondria, giving a total number of mtDNA molecules per human cell of approximately 500. However, the amount of mitochondria per cell also varies by cell type, and an egg cell can contain 100,000 mitochondria, corresponding to up to 1,500,000 copies of the mitochondrial genome (constituting up to 90% of the DNA of the cell).
Sources: en.wikipedia.org
== Screening == Screening for hypothyroidism is performed in the newborn period in many countries, generally using TSH. This has led to the early identification of many cases and thus the prevention of developmental delay. It is the most widely used newborn screening test worldwide. While TSH-based screening will identify the most common causes, the addition of T4 testing is required to pick up the rarer central causes of neonatal hypothyroidism. If T4 determination is included in the screening done at birth, this will identify cases of congenital hypothyroidism of central origin in 1:16,000 to 1:160,000 children. Considering that these children usually have other pituitary hormone deficiencies, early identification of these cases may prevent complications. In adults, widespread screening of the general population is debated. Some organizations (such as the United States Preventive Services Task Force) state that evidence is insufficient to support routine screening, while others (such as the American Thyroid Association) recommend either intermittent testing above a certain age in all sexes or only in women.
== Re-activity (1980–2000) == In 1980, old friend (and fellow ex-Sinner) Dave Machan persuaded Ron to perform again, along with vocalist Kathy Monaco this time in a folk based group called Trinity (Ron played bass for this group). Trinity recorded an albums' worth of material at Dayson Studios (owned by George Day and also home to much of the work done by Ron Wray for the History of Syracuse Music releases) which still remains unreleased. Though Trinity was successful on the nightclub scene, Ron wanted to return to the rock music that was his first love, and tried to re-form The Saint and the Sinners which soon changed their name to East Side Story (later East Side). East Side specialized in classic oldies and seventies hard rock. This band lasted (with virtually the same line-up) for fifteen years before folding in 2000. Some of the members of East Side were Graham Daniels (1984–2000), Larry Brennan (1984–2000), Tom DiRenzo (1988–2000), John Mirra (1991–1993; 1997–2000), Earl "the Pearl" Hamilton (formerly of The New York Flyers now with Redline (1994–1997), Dave Machan (1984–1987) and Barry Glisker (1984–1989).
=== Medicaid overbilling === A fraud investigation by the United States Department of Justice began in 2000 when allegations were brought in two separate lawsuits filed by whistleblowers under the False Claims Act. They alleged that Merck failed to pay proper rebates to Medicaid and other health care programs and paid illegal remuneration to health care providers. On February 7, 2008, Merck agreed to pay more than $650 million to settle charges that it routinely overbilled Medicaid for its most popular medicines. The settlement was one of the largest pharmaceutical settlements in history. The federal government received more than $360 million, plus 49 states and Washington, DC, received over $290 million. One whistleblower received a $68 million reward. Merck made the settlement without an admission of liability or wrongdoing.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.